Literature DB >> 10077233

Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.

A A Weber1, S Reimann, K Schrör.   

Abstract

1. The thienopyridine clopidogrel is a specific inhibitor of ADP-induced platelet aggregation ex vivo. No direct effects of clopidogrel (< or = 100 microM) on platelet aggregation in vitro have been described so far. 2. Possible in vitro antiaggregatory effects (turbidimetry) of clopidogrel were studied in human platelet-rich plasma and in washed platelets. 3. Incubation of platelet-rich plasma with clopidogrel (< or = 100 microM) for up to 8 h did not result in any inhibition of ADP (6 microM)-induced platelet aggregation. 4. Incubation of washed platelets with clopidogrel resulted in a time- (maximum effects after 30 min) and concentration-dependent (IC50 1.9+/-0.3 microM) inhibition of ADP (6 microM)-induced platelet aggregation. Clopidogrel (30 microM) did not inhibit collagen (2.5 microg ml(-1))-, U46619 (1 microM)- or thrombin (0.1 u ml(-1))-induced platelet aggregation. The inhibition of ADP-induced aggregation by clopidogrel (30 microM) was insurmountable indicating a non-equilibrium antagonism of ADP actions. The R enantiomer SR 25989 C (30 microM) was significantly less active than clopidogrel (30 microM) in inhibiting platelet aggregation (32+/-5% vs 70+/-1% inhibition, P < 0.05, n = 5). 5. In washed platelets, clopidogrel (< or = 30 microM) did not significantly reverse the inhibition of prostaglandin E1 (1 microM)-induced platelet cyclic AMP formation by ADP (6 microM). 6. The antiaggregatory effects of clopidogrel were unchanged when the compound was removed from the platelet suspension. However, platelet inhibition by clopidogrel was completely abolished when albumin (350 mg ml(-1)) was present in the test buffer. 7. It is concluded that clopidogrel specifically inhibits ADP-induced aggregation of washed platelets in vitro without hepatic bioactivation. Inhibition of ADP-induced platelet aggregation by clopidogrel in vitro occurs in the absence of measurable effects on the reversal of PGE1-stimulated cyclic AMP by ADP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10077233      PMCID: PMC1565815          DOI: 10.1038/sj.bjp.0702276

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Characterization of P2x1 purinoreceptors on rat platelets: effect of clopidogrel.

Authors:  P Savi; J Bornia; V Salel; M Delfaud; J M Herbert
Journal:  Br J Haematol       Date:  1997-09       Impact factor: 6.998

2.  Antiplatelet effect of ticlopidine after coronary stenting.

Authors:  F J Neumann; M Gawaz; T Dickfeld; A Wehinger; H Walter; R Blasini; A Schomig
Journal:  J Am Coll Cardiol       Date:  1997-06       Impact factor: 24.094

3.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

4.  Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine.

Authors:  P Savi; M C Laplace; J P Maffrand; J M Herbert
Journal:  J Pharmacol Exp Ther       Date:  1994-05       Impact factor: 4.030

5.  ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes--an effect selectively blocked by the thienopyridine clopidogrel.

Authors:  C Gachet; P Savi; P Ohlmann; J P Maffrand; K H Jakobs; J P Cazenave
Journal:  Thromb Haemost       Date:  1992-07-06       Impact factor: 5.249

6.  Direct inhibition of platelet function by organic nitrates via nitric oxide formation.

Authors:  A A Weber; H Strobach; K Schrör
Journal:  Eur J Pharmacol       Date:  1993-09-15       Impact factor: 4.432

7.  Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors.

Authors:  C Gachet; M Cattaneo; P Ohlmann; B Hechler; A Lecchi; J Chevalier; D Cassel; P M Mannucci; J P Cazenave
Journal:  Br J Haematol       Date:  1995-10       Impact factor: 6.998

8.  The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A.

Authors:  P Savi; J Combalbert; C Gaich; M C Rouchon; J P Maffrand; Y Berger; J M Herbert
Journal:  Thromb Haemost       Date:  1994-08       Impact factor: 5.249

9.  Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel.

Authors:  P Savi; J M Herbert; A M Pflieger; F Dol; D Delebassee; J Combalbert; G Defreyn; J P Maffrand
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

10.  cAMP is not an important messenger for ADP-induced platelet aggregation.

Authors:  P Savi; A M Pflieger; J M Herbert
Journal:  Blood Coagul Fibrinolysis       Date:  1996-03       Impact factor: 1.276

View more
  19 in total

1.  Evaluating platelet aggregation dynamics from laser speckle fluctuations.

Authors:  Zeinab Hajjarian; Diane M Tshikudi; Seemantini K Nadkarni
Journal:  Biomed Opt Express       Date:  2017-06-30       Impact factor: 3.732

2.  Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747.

Authors:  A Sugidachi; F Asai; K Yoneda; R Iwamura; T Ogawa; K Otsuguro; H Koike
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 3.  Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.

Authors:  Nicola Ferri; Alberto Corsini; Stefano Bellosta
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

4.  The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.

Authors:  A Sugidachi; F Asai; T Ogawa; T Inoue; H Koike
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

5.  Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery.

Authors:  Laura Molero; Antonio López-Farré; Petra J Mateos-Cáceres; Ruth Fernández-Sánchez; María Luisa Maestro; Jacobo Silva; Enrique Rodríguez; Carlos Macaya
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

6.  Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.

Authors:  A A Weber; M Braun; T Hohlfeld; B Schwippert; D Tschöpe; K Schrör
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

7.  Does glycoprotein IIIa gene (Pl(A)) polymorphism influence clopidogrel resistance? : a study in older patients.

Authors:  Elod Papp; Viktoria Havasi; Judit Bene; Katalin Komlosi; Gabor Talian; Gergely Feher; Beata Horvath; Laszlo Szapary; Kalman Toth; Bela Melegh
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 8.  Blood cells: an historical account of the roles of purinergic signalling.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2015-08-11       Impact factor: 3.765

9.  Clopidogrel variability: role of plasma protein binding alterations.

Authors:  Shobana Ganesan; Craig Williams; Cheryl L Maslen; Ganesh Cherala
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

10.  MiR-223 or miR-126 predicts resistance to dual antiplatelet therapy in patients with ST-elevation myocardial infarction.

Authors:  Xiaojing Li; Qi Yao; Hanbin Cui; Jun Yang; Nan Wu; Yahui Liu; Ying Zhou; Yinwei Zhang; Jia Su; Yezi Xia; Xiaomin Chen
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.